BIOL 5134 3.0 Vacular Biology in Health and Disease

Other Course
BIOL 5134 3.0
Vascular Biology in Health and Disease
(Cross-listed with KAHS 6301 3.0)
Host Program: Kinesiology

Course Description:

Understanding the cellular composition and function of the vascular system provides the basis in this course for discussing the processes of angiogenesis, atherosclerosis, inflammation and ischemia-reperfusion injury with an emphasis on current advances in pharmacological and genetic therapies.

Blood vessel structure and function is dynamic rather than static, allowing the vascular system to respond adaptively to stimuli and to injury. Furthermore, the response of each of the multiple cell types comprising blood vessels will determine overall vascular function. These responses will be taken into account as we discuss in this course the stimuli, signalling pathways and resultant cellular behaviour of the vascular system in various physiological and disease states. How do growing tumours stimulate new blood vessel growth? How can new blood vessel formation be stimulated in damaged cardiac muscle? What initiates the formation of atherosclerotic plaques? What roles do blood vessels play during inflammatory responses? Why are blood vessels dysfunctional following organ transplant? These topics will be discussed by focusing on current understanding of the cellular mechanisms underlying these events and investigating some of the associated novel therapeutic strategies.

Instructor:

Dr. Tara Haas
341 Farquharson
Tel: 736-2100 ext. 77313
e-mail:thaas@yorku.ca

Evaluation:

Midterm Written Exam 25%
Journal Article Presentation 20%
Written Grant Proposal 30%
Final Written Exam 25%
Bibliography:

Fuster, V., Ross R., Topol, E. (eds) Atherosclerosis and coronary artery disease, Lippincott-Raven, Philadelphia, 1996.

Sumpio, B.E. (ed) Hemodynamic forces and vascular cell biology, CRC Press, Boca Raton, 1993.

Draznin,B. and Eckel, R.H. (eds) Diabetes and atherosclerosis : molecular basis and clinical aspects, Elsevier, New York, 1993.

Maragoudakis, M.E. (ed) Molecular, cellular, and clinical aspects of angiogenesis, Plenum Press, New York, 1996.

Steiner,R., Weisz, P.B., Langer, R.(eds) Angiogenesis : key principles--science, technology, medicine, Birkhauser Verlag, Basel, 1992.

Das, D.K. (ed) Cellular, biochemical, and molecular aspects of reperfusion injury, New York Academy of Science, New York, 1997.

Marks, A.R., Taubman, M.B. (eds) Molecular biology of cardiovascular disease, Marcel Dekker, New York, 1997.

Rosengart TK; Lee LY; Patel SR; Sanborn TA; Parikh M; Bergman GW; Hachamovitch R; Szulc M; Kligfield PD; Okin PM; Hahn RT; Devereux RB; Post MR; Hackett NR; Foster T; Grasso TM; Lesser ML; Isom OW; Crystal RG Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999:100(5):468-74

Losordo DW; Vale PR; Isner JM Gene therapy for myocardial angiogenesis. Am Heart J 1999:138(2 Pt 2):132-41.

Rivard A; Silver M; Chen D; Kearney M; Magner M; Annex B; Peters K; Isner JM Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 1999:154(2):355-63

Wylie S; MacDonald IC; Varghese HJ; Schmidt EE; Morris VL; Groom AC; Chambers AF The matrix metalloproteinase inhibitor batimastat inhibits angiogenesis in liver metastases of B16F1 melanoma cells. Clin Exp Metastasis 1999:17(2):111-7

Tarli L; Balza E; Viti F; Borsi L; Castellani P; Berndorff D; Dinkelborg L; Neri D; Zardi L A high-affinity human antibody that targets tumoral blood vessels. Blood 1999:94(1):192-8

Storgard CM; Stupack DG; Jonczyk A; Goodman SL; Fox RI; Cheresh DA Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist J Clin Invest 1999:103(1):47-54
Murakami H; Yayama K; Miao RQ; Wang C; Chao L; Chao J Kallikrein gene delivery inhibits vascular smooth muscle cell growth and neointima formation in the rat artery after balloon angioplasty. Hypertension 1999:34(2):164-70

Shimokawa H Primary endothelial dysfunction: atherosclerosis. J Mol Cell Cardiol 1999:31(1):23-37

Ross R Atherosclerosis--an inflammatory disease N Engl J Med 1999:340(2):115-26

Mann MJ; Gibbons GH; Hutchinson H; Poston RS; Hoyt EG; Robbins RC; Dzau VJ Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. Proc Natl Acad Sci U S A 1999:96(11):6411-6

Ramos CL; Huo Y; Jung U; Ghosh S; Manka DR; Sarembock IJ; Ley K Direct demonstration of P-selectin- and VCAM-1-dependent mononuclear cell rolling in early atherosclerotic lesions of apolipoprotein E- deficient mice. Circ Res 1999:84(11):1237-44

Jung U; Norman KE; Scharffetter-Kochanek K; Beaudet AL; Ley K Transit time of leukocytes rolling through venules controls cytokine-induced inflammatory cell recruitment in vivo. J Clin Invest 1998:102(8):1526-33

Cines DB; Pollak ES; Buck CA; Loscalzo J; Zimmerman GA; McEver RP; Pober JS; Wick TM; Konkle BA; Schwartz BS; Barnathan ES; McCrae KR; Hug BA; Schmidt AM; Stern DM Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998:91(10):3527-61

Jones SP; Girod WG; Palazzo AJ; Granger DN; Grisham MB; Jourd'Heuil D; Huang PL; Lefer DJ Myocardial ischemia-reperfusion injury is exacerbated in absence of endothelial cell nitric oxide synthase. Am J Physiol 1999:276(5 Pt 2):H1567-73.

Kubes P, et al. Inhaled NO impacts vascular but not extravascular compartments in postischemic peripheral organs. Am J Physiol. 1999:277(2 Pt 2):H676-82.